LATS1 and renal cell carcinoma: Increased RCC apoptosis by tazemetostat was rescued by inhibition of LATS1 (control, tazemetostat, siLATS1, tazemetostat + siLATS1: 2.8, 10.8, 1.9, and 3.5% for Caki‐1; 2.2, 8.3, 1.4, and 2.4% for ACHN; and 4.3, 16.6, 1.1, and 12.7% for UOK‐276, respectively) (Fig. 3D and Fig. S3D).